enVVeno Medical (NASDAQ:NVNO) Raised to “Hold” at Wall Street Zen

enVVeno Medical (NASDAQ:NVNO) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

Several other equities analysts have also recently commented on NVNO. LADENBURG THALM/SH SH upgraded enVVeno Medical from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 6th. Zacks Research upgraded shares of enVVeno Medical to a “hold” rating in a research note on Tuesday, July 7th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of enVVeno Medical in a research note on Friday, September 25th. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, enVVeno Medical has an average rating of “Hold”.

enVVeno Medical Stock Performance

Shares of NVNO opened at $6.65 on Friday. enVVeno Medical has a one year low of $6.55 and a one year high of $26.72. The stock has a 50-day moving average price of $9.39 and a 200 day moving average price of $10.30. The company has a market capitalization of $4.59 million, a P/E ratio of -0.34 and a beta of 1.29.

enVVeno Medical (NASDAQ:NVNO) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($5.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.69) by ($0.68). As a group, equities research analysts forecast that enVVeno Medical will post -16.19 earnings per share for the current fiscal year.

enVVeno Medical Company Profile

enVVeno Medical Corporation (NASDAQ: NVNO) is a medical device company focused on developing bioprosthetic solutions for vascular and cardiovascular diseases. The company’s technologies are designed to address conditions for which existing medical and surgical treatments may be limited or ineffective.

Its lead product candidate is the VenoValve, an investigational surgically implanted tissue-based valve intended to treat chronic deep venous insufficiency, including symptoms associated with post-thrombotic syndrome.